The FDA has received 28,973 adverse event reports for dogs that name Oclacitinib.
- 28,973 reports name Oclacitinib in dogs, which is 2.9% of all 1,001,380 dog reports. A report counts under every active ingredient it names.
- 30% are marked serious and 5.0% record a death or euthanasia; across all dog reports those figures are 29% and 5.4%.
- 29% are complaints that the product did not work (38% across all dog reports).
- The clinical signs reported most are lack of efficacy, vomiting and ineffective, atopy control.
- The FDA lists 2 approved animal drug applications containing Oclacitinib for dogs, the earliest approved in 2013.
- None of this is a rate. The FDA data does not record how many dogs were given Oclacitinib, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All dog reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 8,766 | 30% | 29% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 1,449 | 5.0% | 5.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 8,544 | 29% | 38% |
| Seizurea seizure or convulsion is among the clinical signs | 1,238 | 4.3% | 4.4% |
| Not used per labelthe report says the product was not used the way its label directs | 8,910 | 31% | 21% |
Where on the body do the reported signs sit?
Not on the body: Did not work 28% Whole body 14% How it was given 2.5%
- Did not work28%lack of efficacy, ineffective, atopy control, ineffective, loss of effect, partial lack of efficacy
- Stomach and gut27%vomiting, diarrhoea, anorexia, decreased appetite and 2 more
- Blood and organ tests16%other abnormal test result, elevated alanine aminotransferase (alt), elevated serum alkaline phosphatase (sap), leucopenia and 1 more
- Whole body14%lethargy, lethargy, death by euthanasia, death
- Thirst and urination4.4%polydipsia, polyuria
- Brain and nerves3.6%seizure
- How it was given2.5%overdose
- Behaviour2.5%behavioural disorder
- Skin and coat1.9%dermal mass
Each figure is a share of sign mentions among the 25 signs reported most for Oclacitinib in dogs. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- Lack of efficacy3,814 13%
- Vomiting3,401 12%
- INEFFECTIVE, ATOPY CONTROL2,681 9.3%
- Diarrhoea2,324 8.0%
- Lethargy2,145 7.4%
- INEFFECTIVE, LOSS OF EFFECT1,798 6.2%
- Other abnormal test result1,418 4.9%
- Elevated alanine aminotransferase (ALT)1,163 4.0%
Reports received per year
Is it approved for dogs?
The FDA lists 2 approved animal drug applications containing Oclacitinib for dogs, the earliest approved in 2013.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| ApoquelZoetis Inc. | Tablet RX | Dog | 2013 | 141-345 |
| Apoquel ChewableZoetis Inc. | Chewable Tablets RX | Dog | 2023 | 141-555 |
From the FDA record for Apoquel: APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. See Oclacitinib in cats (463 reports). Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Selamectin in dogs29,523
- Melarsomine in dogs22,745
- Lufenuron in dogs36,856
- Bedinvetmab in dogs19,619
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.